Tamborska, Arina A 
ORCID: 0000-0003-4661-8407, Singh, Bhagteshwar ORCID: 0000-0002-9039-3674, Leonhard, Sonja E, Hodel, Eva Maria ORCID: 0000-0001-5821-1685, Stowe, Julia, Watson-Fargie, Taylor, Fernandes, Peter M, Themistocleous, Andreas C, Roelofs, Jacob, Brennan, Kathryn et al (show 5 more authors)
(2022)
Guillain-Barre syndrome following SARS-CoV-2 vaccination in the UK: a prospective surveillance study.
BMJ NEUROLOGY OPEN, 4 (2).
e000309-.
Abstract
<h4>Objective</h4>To investigate features of Guillain-Barré syndrome (GBS) following SARS-CoV-2 vaccines and evaluate for a causal link between the two.<h4>Methods</h4>We captured cases of GBS after SARS-CoV-2 vaccination through a national, open-access, online surveillance system. For each case, the certainty of GBS was graded using the Brighton criteria, and the relationship to the vaccine was examined using modified WHO Causality Assessment criteria. We compared age distribution of cases with that of prepandemic GBS cases and clinical features with the International GBS Outcome Study (IGOS).<h4>Results</h4>Between 1 January and 30 June 2021, we received 67 reports of GBS following the ChAdOx1 vaccine (65 first doses) and three reports following the BNT162b2 vaccine (all first doses). The causal association with the vaccine was classified as probable for 56 (80%, all ChAdOx1), possible for 12 (17%, 10 ChAdOx1) and unlikely for two (3%, 1 ChAdOx1). A greater proportion of cases occurred in the 50-59 age group in comparison with prepandemic GBS. Most common clinical variants were sensorimotor GBS (n=55; 79%) and facial diplegia with paraesthesias (n=10; 14%). 10% (n=7/69) of patients reported an antecedent infection, compared with 77% (n=502/652) of the IGOS cohort (p<0.00001). Facial weakness (63% (n=44/70) vs 36% (n=220/620); p<0.00001) and sensory dysfunction (93% (n=63/68) vs 69% (n=408/588); p=0.00005) were more common but disease severity and outcomes were similar to the IGOS study.<h4>Interpretation</h4>Most reports of GBS followed the first dose of ChAdOx1 vaccine. While our study cannot confirm or refute causation, this observation, together with the absence of alternative aetiologies, different than expected age distribution and the presence of unusual clinical features support a causal link. Clinicians and surveillance bodies should remain vigilant to the possibility of this very rare adverse event and its atypical variants.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | clinical neurology, guillain-barre syndrome, COVID-19 |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Clinical Directorate Faculty of Health and Life Sciences > Institute of Infection, Veterinary and Ecological Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 26 Jul 2022 08:44 |
| Last Modified: | 18 Jan 2023 20:55 |
| DOI: | 10.1136/bmjno-2022-000309 |
| Open Access URL: | https://neurologyopen.bmj.com/content/4/2/e000309 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3159309 |
Dimensions
Dimensions
